Q3 2024 · 13F-HR
Avoro Capital Advisors LLCholdings as filed
Filed 2024-11-14 · accession 0001104659-24-118335
$6.86B
Reported value
36
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP | $1.02B | 14.9% | 2,858,888 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA | $744.9M | 10.9% | 4,988,888 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $671.3M | 9.79% | 1,238,467 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $477.3M | 6.96% | 2,622,222 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $430.6M | 6.28% | 2,029,000 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC. | $320.4M | 4.67% | 11,111,111 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $319.2M | 4.65% | 2,555,555 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $315.8M | 4.60% | 6,875,000 | Common | SOLE |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC. | $247.5M | 3.61% | 23,175,000 | Common | SOLE |
| 46116X101 | ITCIEUR | INTRA-CELLULAR THERAPIES INC | $223.2M | 3.25% | 3,050,000 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $223.1M | 3.25% | 5,666,666 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $213.0M | 3.11% | 4,500,000 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $190.5M | 2.78% | 4,309,590 | Common | SOLE |
| 04280A100 | ARWR | ARROWHEAD PHARMACEUTICALS INC. | $172.2M | 2.51% | 8,888,888 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $143.3M | 2.09% | 2,038,015 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $139.7M | 2.04% | 2,770,100 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $134.3M | 1.96% | 1,175,000 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $110.1M | 1.61% | 2,181,000 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $90.2M | 1.31% | 11,865,000 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $74.9M | 1.09% | 3,888,437 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $70.1M | 1.02% | 8,060,000 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $69.2M | 1.01% | 3,541,505 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $67.7M | 0.99% | 1,355,000 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $57.1M | 0.83% | 2,222,222 | Common | SOLE |
| 56400P706 | MNKD | MANNKIND CORP | $55.0M | 0.80% | 8,750,000 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL INC | $46.1M | 0.67% | 830,000 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $44.8M | 0.65% | 12,345,678 | Common | SOLE |
| 462260100 | IOVA | IOVANCE BIOTHERAPEUTICS INC | $39.8M | 0.58% | 4,240,000 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $37.5M | 0.55% | 18,650,000 | Common | SOLE |
| 61225M102 | GLUE | MONTE ROSA THERAPEUTICS INC | $30.7M | 0.45% | 5,790,236 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $26.4M | 0.39% | 700,000 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC. | $23.3M | 0.34% | 650,000 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $17.6M | 0.26% | 598,600 | Common | SOLE |
| 00032Q104 | WHWK | AADI BIOSCIENCES INC | $5.9M | 0.09% | 2,849,402 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $924,337 | 0.01% | 22,029 | Common | SOLE |
| 457669957 | — | INSMED INC | $125,000 | 0.00% | 50,000 | PUT | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.